227. Osler disease Clinical trials / Disease details
Clinical trials : 54 / Drugs : 73 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03954782 (ClinicalTrials.gov) | June 22, 2020 | 15/5/2019 | Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. | Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. A National, Randomized, Multicentre Phase II Study | Telangiectasia, Hereditary Hemorrhagic;Rendu Osler Disease | Drug: Nintedanib 150 mg and 100 mg soft capsules;Drug: Oral treatment of placebo soft capsule | Hospices Civils de Lyon | NULL | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | France |